Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | ALK tyrosine kinase receptor | ||
Ligand | BDBM50396253 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_863887 (CHEMBL2176371) | ||
IC50 | 2±n/a nM | ||
Citation | Lewis, RT; Bode, CM; Choquette, DM; Potashman, M; Romero, K; Stellwagen, JC; Teffera, Y; Moore, E; Whittington, DA; Chen, H; Epstein, LF; Emkey, R; Andrews, PS; Yu, VL; Saffran, DC; Xu, M; Drew, A; Merkel, P; Szilvassy, S; Brake, RL The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem55:6523-40 (2012) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
ALK tyrosine kinase receptor | |||
Name: | ALK tyrosine kinase receptor | ||
Synonyms: | ALK | ALK tyrosine kinase receptor (ALK) | ALK_HUMAN | Anaplastic lymphoma kinase | CD_antigen: CD246 | ||
Type: | Protein | ||
Mol. Mass.: | 176453.10 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q9UM73 | ||
Residue: | 1620 | ||
Sequence: |
| ||
BDBM50396253 | |||
n/a | |||
Name | BDBM50396253 | ||
Synonyms: | CHEMBL2172331 | ||
Type | Small organic molecule | ||
Emp. Form. | C29H36FN5O4S | ||
Mol. Mass. | 569.691 | ||
SMILES | CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCS(=O)(=O)CC3)cc12 |r,wU:9.12,6.5,(19.6,-10.76,;18.09,-10.45,;17.61,-8.98,;17.06,-11.59,;15.55,-11.28,;14.53,-12.42,;15.08,-9.81,;13.57,-9.49,;13.09,-8.04,;14.12,-6.89,;15.62,-7.19,;16.1,-8.66,;13.64,-5.43,;14.54,-4.17,;16.08,-4.16,;16.84,-2.82,;16.07,-1.49,;18.38,-2.81,;19.16,-4.14,;20.7,-4.13,;21.46,-2.79,;23,-2.78,;20.67,-1.46,;19.14,-1.47,;13.62,-2.92,;12.15,-3.41,;10.81,-2.64,;9.49,-3.41,;9.48,-4.96,;8.15,-5.73,;6.82,-4.96,;6.82,-3.42,;5.49,-2.65,;4.15,-3.41,;2.61,-3.41,;3.38,-2.07,;4.15,-4.95,;5.48,-5.73,;10.82,-5.73,;12.16,-4.96,)| | ||
Structure |